

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau9905200-3
1905 copy

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 413/12, A61K 31/42, C07D 413/14, A61K 9/19, C07D 261/16		A1	(11) International Publication Number: WO 98/49162
			(43) International Publication Date: 5 November 1998 (05.11.98)
(21) International Application Number: PCT/US98/06680			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 2 April 1998 (02.04.98)			
(30) Priority Data: 08/847,797 28 April 1997 (28.04.97) US 08/938,444 26 September 1997 (26.09.97) US			
(71) Applicant (for all designated States except US): TEXAS BIOTECHNOLOGY CORPORATION [US/US]; Suite 1920, 7000 Fannin, Houston, TX 77030 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): WU, Chengde [CN/US]; 7530 Brompton Road #824, Houston, TX 77025 (US). BLOK, Natalie [US/US]; 3610 Lake Street, Houston, TX 77098 (US). KOGAN, Timothy [US/US]; 3422 Creekstone Drive, Sugarland, TX 77479 (US). KELLER, Karin [US/US]; 8330 El Mundo #808, Houston, TX 77054 (US). WOODARD, Patricia [US/US]; 3422 Creekstone Drive, Sugarland, TX 77479 (US).			
(74) Agent: SEIDMAN, Stephanie, L.; Heller Ehrman White & McAuliffe, Suite 700, 4250 Executive Square, La Jolla, CA 92037 (US).			Published <i>With international search report.</i>
(54) Title: SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS			
(57) Abstract Thienyl-, furyl- and pyrrolyl-sulfonamides, pharmaceutically-acceptable salts of sulfonamides, formulations of salts and the sulfonamides, and methods for modulating or altering the activity of the endothelin family of peptides using the formulations and sulfonamides are provided. In particular, formulations of sodium salts of N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides are provided. A process of preparing an alkali metal salt of a hydrophobic sulfonamide is provided. The process includes the step of dissolving a free sulfonamide in an organic solvent in the presence of a saturated alkali metal salt solution and recovering the formed sulfonamide salt from the organic phase.			